Comparison of efficacy and adverse reaction of two chemotherapy regimens for locally advanced cervical cancer with concurrent chemoradiotherapy / 中国生化药物杂志

ABSTRACT

Objective To compare the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin and docetaxel in combination with classical single drug cisplatin in locally advanced cervical cancer. Methods From 2010 to 2014 in Baoji hospital affiliated to Xi'an medical university, 48 patients with advanced cervical cancer( stage II B-stage IV A), who received concurrent chemoradiotherapy were selected, all patients were treated with 3DCRT technique, pelvic external irradiation combined with intracavitary brachytherapy, the dose of radiotherapy reached a radical dose. According to the same chemotherapy divided into docetaxel cisplatin group (group A, n=24), specific drugs Cisplatin 60mg/ (m2?d) d1 intravenous drip, or 2 days, docetaxel 60mg/ (m2?d) d1 intravenous drip, repeated every 21 days, a total of 3 cycles of cisplatin group; (group B, n=24), cisplatin 40mg/(m2?d)intravenous drip, 1 times a week, a total of 5~6 weeks. The long-term clinical efficacy and adverse effects of radiotherapy and chemotherapy were compared between the two groups. Results The recent effective rate in group A and group B respectively were 91.7 % and 87.5%, the difference was not statistically significant; 2 year progression free survival in group A and group B respectively was 75.00 %and 54.2 %, the difference was statistically significant (P<0.05); Grade III and IV hematologic toxicity in group A and group B respectively was 45.9 %, 33.3 %, the differenc was statistically significant , (P<0.05). Acute and late gastrointestinal reactions, urinary tract reaction rate in the two groups had no significant difference. Conclusion There was no significant difference between radical radiotherapy and cisplatin combined with docetaxel and cisplatin for locally advanced cervical cancer and compare the efficacy, 2 year progression free survival rate was significantly higher than single drug cisplatin group and cisplatin combined with docetaxel chemotherapy group but hematologic toxicities were obvious, and non-hematologic adverse reactions of radiotherapy and chemotherapy without significant difference.